Pharma Focus America

Endogenex™ Announces Presentation of First Human Clinical Experience

Friday, May 05, 2023

Endogenex, Inc., a clinical stage medical device company, announced presentations of early clinical experience using its ReCET™ System in three oral presentations at Digestive Disease Week (DDW) from May 6 – 9, 2023 in Chicago, IL.

The REGENT-1 Study abstract (abstract #46) titled "Duodenal Mucosal Regeneration Induced by Endoscopic Pulsed Electric Field Treatment Improves Glycemic Controls in Patient with Type II Diabetes – Interim Results from First-in-Human Study" will be presented on Saturday, May 6th by Dr. Adrian Sartoretto from The BMI Clinic, North South Wales, Australia.

On Tuesday, May 9th, a video presentation "Endoscopic Re-Cellularization Via Electroporation Therapy (ReCET)" (abstract  #1108) will be presented by Dr. Khushboo Gala from Mayo Clinic, Rochester, MN and an oral presentation of "Re-Cellularization via Electroporation Therapy (ReCET) Combined with GLP-1 RA to Replace Insulin Therapy in Patients with Type 2 Diabetes – 6 Month Results of the EMINENT Study" (abstract #1272) will be presented by Dr. Celine B.E. Busch from Amsterdam University Medical Center, Amsterdam, Netherlands.

"We are excited to share the first clinical experience for the ReCET System with the scientific and medical community at this year's Digestive Disease Week" said Stacey Pugh, Endogenex CEO. "We have collaborated with top tier institutions globally to evaluate the ReCET Therapy in the REGENT-1 and EMINENT studies and are pleased to share these initial outcomes with the broader clinical community."



Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024